A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia (Certolizumab Pegol)

Trial Profile

A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia (Certolizumab Pegol)

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Spondylitis
  • Focus Pharmacokinetics
  • Acronyms CRIB
  • Sponsors UCB
  • Most Recent Events

    • 22 Mar 2018 Results published in the UCB Media Release
    • 22 Mar 2018 According to an UCB media release, The approval of the CIMZIA label update is based on data from the post-marketing pharmacokinetic CRIB and CRADLE studies
    • 08 Nov 2017 Results assessing placental transfer of Certolizumab-pegol from mothers to infants, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top